Relay Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RLAY research report →
Range $18 – $31
Price Chart
About the company
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions.
- CEO
- Sanjiv K. Patel
- IPO
- 2020
- Employees
- 193
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on RLAY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.32B
- P/E
- -12.55
- PEG
- -0.57
- P/S
- 417.11
- P/B
- 4.49
- EV/EBITDA
- -14.73
- Div Yield
- 0.00%
- Gross Margin
- -566.59%
- Op Margin
- -2999.38%
- Net Margin
- -2763.64%
- ROE
- -42.27%
- ROIC
- -33.72%
Latest fiscal year · YoY change
- Revenue
- $15.36M+53.4%
- Gross Profit
- $11.80M+103.9%
- Op Income
- $-302,738,000
- Net Income
- $-276,479,000+18.1%
- EPS
- $-1.61+31.8%
- OCF Growth
- +5.5%
- FCF Growth
- +6.1%
- 52W High
- $21.27
- 52W Low
- $3.31
- 50D MA
- $18.52
- 200D MA
- $12.20
- Beta
- 1.70
- RSI (14)
- 52
- Avg Volume
- 3.52M
No earnings-call transcripts are available for RLAY yet.
- Free Float
- 78.3%
- Shares Outstanding
- 219.14M
- Float Shares
- 171.50M
of shares held by institutions
247 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for RLAY, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel GoldmanHouse · NY10 | Sell | Jul 12, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Sb Investment Advisers (Uk) Ltd | 27.90M | 0 |
| Fmr LLC | 20.11M | ▲ 16.41M |
| Casdin Capital, LLC | 16.04M | ▲ 1.62M |
| Blackrock, Inc. | 15.29M | ▲ 2.31M |
| Perceptive Advisors LLC | 14.11M | ▲ 4.36M |
| Commodore Capital LP | 12.00M | ▼ 5.00M |
| State Street Corp | 10.13M | ▲ 3.89M |
| Vanguard Group Inc | 9.69M | ▲ 295.70K |
| Vanguard Capital Management LLC | 8.96M | ▲ 1.58M |
| Price T Rowe Associates Inc | 7.71M | ▲ 5.78M |
| Nextech Invest, Ltd. | 6.78M | ▲ 1.25M |
| Bellevue Group AG | 6.19M | ▼ 1.61M |
Held by 254 ETFs
Biggest fund positions in RLAY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 17, 26 | Patel Sanjiv | sell | 48,199 |
| Aug 14, 26 | Catinazzo Thomas | sell | 17,717 |
| Jul 28, 26 | Catinazzo Thomas | sell | 1,459 |
| Jul 28, 26 | Rahmer Peter | sell | 748 |
| Jul 28, 26 | Bergstrom Donald A | sell | 2,237 |
| Jul 6, 26 | Bergstrom Donald A | sell | 8,660 |
| Jun 30, 26 | Patel Sanjiv | other | 3,056 |
| Jul 7, 26 | Patel Sanjiv | sell | 48,199 |
| Jul 6, 26 | Catinazzo Thomas | sell | 17,717 |
| Jun 30, 26 | Rahmer Peter | other | 3,056 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RLAY coverage
Recent articles, reports, and earnings notes.
Want a deeper read on RLAY?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE
defenseworld.net · Aug 20
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
zacks.com · Aug 17
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
zacks.com · Aug 6
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
globenewswire.com · Aug 6
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
globenewswire.com · Jul 30
Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?
zacks.com · Jul 30
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
prnewswire.com · Jul 23
Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year
fool.com · Jun 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.